ClinicalTrials.gg
CompletedNCT00481663Updated Apr 4, 2017

A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)

A Phase 2 interventional study of Sitagliptin and Placebo to sitagliptin in Type II Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-04-04.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 years 9 months after the study started (first participant enrolled Aug 2003, registered Jun 2007).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
555
Allocation
Randomized
Ages
21 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
24th of 197
555 · median 102
Started
2003
the only one that year
Phase 2
10 of 198
none open now
Registered
29th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 24th largest by enrollment of the 197 interventional ones that give a count, is the only one that started in 2003, is one of 10 in phase 2, and was the 29th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 21 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

A study of different doses of MK-0431 in participants with type 2 diabetes mellitus. There have been 3 extensions to the base study (Extension 1: up to Week 52, Extension 2: up to Week 106, and Extension 3: up to Week 158). The primary hypothesis for the study is that In participants with type 2 diabetes who have inadequate glycemic control, after 12 weeks of treatment, a dose-response will be seen across once-daily doses of MK-0431 in lowering hemoglobin A1C (HbA1c).

03

Conditions studied

  • Type II Diabetes Mellitus
04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and non-pregnant women
  • Fasting plasma glucose >= 130 mg/dL
  • >=6.5% and >10.0%

Exclusion criteria

Exclusion Criteria:

  • You have a history of type I diabetes
  • You are on a weight loss program with ongoing weight loss or taking weight loss medication
  • You have had surgery within 30 days
  • You hvae or C.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
555 participants (actual)

Study arms

  • Experimental
    Sitagliptin 25 mg once daily

    Sitaglipin (MK-0431), 25 mg, once daily for 12 weeks, orally. Due to interim analysis of this study and another Phase IIB study, participants in this arm were switched into the 100-mg once daily arm during either the first or initiation of the second extensions study periods.

    Drug: Sitagliptin · Drug: Rescue

  • Experimental
    Sitagliptin 50 mg once daily

    Sitagliptin, 50 mg, once daily for 12 weeks, orally. Due to interim analysis of this study and another Phase IIB study, participants in this arm were switched into the 100-mg once daily arm during either the first or initiation of the second extensions study periods.

    Drug: Sitagliptin · Drug: Rescue

  • Experimental
    Sitaglipin 100 mg once daily

    Sitagliptin, 100 mg, once daily for 158 weeks, orally

    Drug: Sitagliptin · Drug: Rescue

  • Experimental
    Sitagliptin 50 mg twice daily

    Sitagliptin 50 mg, twice daily for 12 weeks, orally. Due to interim analysis of this study and another Phase IIB study, participants in this arm were switched into the 100-mg once daily arm during either the first or initiation of the second extensions study periods.

    Drug: Sitagliptin · Drug: Rescue

  • Placebo comparator
    Placebo to Sitagliptin → Metformin

    Placebo to Sitagliptin, once daily, orally for 12 weeks. Participants randomized to the placebo treatment group during the base study were reallocated to treatment with metformin 850 mg twice daily (b.i.d., initiated with 850 mg q.d. for 4 weeks then force titrated to 850 mg b.i.d.) during either the first or initiation of the second extensions study periods.

    Drug: Placebo to sitagliptin · Drug: Metformin · Drug: Rescue

Interventions

  • DrugPlacebo to sitagliptin
  • DrugMetformin
  • DrugRescue

    Patients whose FPG \>240 mg/dL from Week 16 or HbA1C \>8.5% from Week 25 up to (not including) Week 52 could receive rescue antihyperglycemic therapy with pioglitazone, and remain in the extension study (Extension 1). Participants were eligible for rescue with pioglitazone 30 mg (or rosiglitazone in countries where pioglitazone was not licensed) if they met the following criteria: from Week 16 and during the second extension: FPG consistently \>240 mg/dL (repeated and confirmed within 3 to 7 days); from Week 52 up to (not including) Week 70: HbA1C \>8%; from Week 70 up to (not including) Visit 21/Week 106: HbA1C \>7.5% (Extension 2). Participants placed on rescue therapy with pioglitazone (rosiglitazone where pioglitazone is not available) in the first or second extensions were not eligible for enrollment in the third extension. Rescue therapy was not available in the third extension.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in HbA1C at Week 12

    Time frame: Baseline and Week 12

  2. Number of Participants Who Experienced One or More Adverse Events (AE) up to Week 14

    Time frame: Up to Week 14

  3. Number of Participants Who Experienced One or More AE up to Week 54

    Time frame: Up to Week 54

  4. Number of Participants Who Experienced One or More AE up to Week 108

    Time frame: Up to Week 108

  5. Number of Participants Who Experienced One or More AE up to Week 160

    Time frame: Up to Week 160

  6. Number of participants Who Discontinued Study Treatment Due to An AE up to Week 12

    Time frame: Up to Week 12

  7. Number of participants Who Discontinued Study Treatment Due to An AE up to Week 52

    Time frame: Up to Week 52

  8. Number of participants Who Discontinued Study Treatment Due to An AE up to Week 106

    Time frame: Up to Week 106

  9. Number of participants Who Discontinued Study Treatment Due to An AE up to Week 158

    Time frame: Up to Week 158

Secondary outcomes

  1. Change from Baseline in HbA1C at Week 52

    Time frame: Baseline and Week 52

  2. Change from Baseline in HbA1C at Week 106

    Time frame: Baseline and Week 106

  3. Change from Baseline in HbA1C at Week 158

    Time frame: Baseline and Week 158

  4. Change from Baseline in Fasting Plasma Glucose (FPG) at Week 12

    Time frame: Baseline and Week 12

  5. Change from Baseline in FPG at Week 52

    Time frame: Baseline and Week 52

  6. Change from Baseline in FPG at Week 106

    Time frame: Baseline and Week 106

  7. Change from Baseline in FPG at Week 158

    Time frame: Baseline and Week 158

  8. Change from Baseline in Body Weight at Week 12

    Time frame: Baseline and Week 12

  9. Change from Baseline in Body Weight at Week 52

    Time frame: Baseline and Week 52

  10. Change from Baseline in Body Weight at Week 106

    Time frame: Baseline and Week 106

  11. Change from Baseline in Body Weight at Week 158

    Time frame: Baseline and Week 158

  12. Change From Baseline in Serum Fructosamine at Week 12

    Time frame: Baseline and Week 12

  13. Change From Baseline in Daily Seven-Point Fingerstick Glucose Average at Week 12

    Time frame: Baseline and Week 12

  14. Change From Baseline in Daily Seven-Point Fingerstick Glucose Average at Week 52

    Time frame: Baseline and Week 52

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP; Sitagliptin Study 014 Investigators. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin. 2007 Jun;23(6):1329-39. doi: 10.1185/030079907X188152. Epub 2007 Apr 30. PubMed 17559733 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2003 to primary completion in Jul 2004, 11 months.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 11 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2007
First posted
Jun 4, 2007
StartActual
Aug 19, 2003
Primary completionActual
Jul 21, 2004
CompletionActual
May 14, 2006
Last update
Apr 4, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00481663
Responsible party
Sponsor
First posted
Jun 4, 2007
Start date
Aug 19, 2003
Primary completion
Jul 21, 2004
Completion
May 14, 2006
Last update
Apr 4, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion